Popular Morning Sickness Drug Safe in Pregnancy, Study Finds

Metoclopramide (INN)   is an antiemetic and gastroprokinetic agent. It belongs to a group of medicines called ´dopaminergic´ blockers. It is commonly used to treat nausea and vomiting, to facilitate gastric emptying in people with gastroparesis, and as a treatment for the gastric stasis often associated with migraine headaches.

Ref : http://jama.jamanetwork.com/article.aspx?articleid=1752754

Popular Morning Sickness Drug Safe in Pregnancy, Study Finds - Drugs.com MedNews

Overexpressed protein to be culprit in certain thyroid cancers

A specific protein once thought to exist only in the brain may play a crucial role in a deadly form of thyroid cancer, as well as other cancers, and provide a fresh target for researchers seeking ways to stop its progression, UT Southwestern Medical Center researchers report ....

Dr. Bibb and Dr. Nwariaku teamed up and launched a study of both human and mouse thyroid cancer cells. They discovered that Cdk5 was present in specific cells of the thyroid called C cells, and that the protein could escape normal cellular control and cause the cancer in both humans and mice.

Now, with the help of other UT Southwestern scientists, Dr. Bibb and Dr. Nwariaku, both members of the Harold C. Simmons Cancer Center, are making important progress in their efforts to develop new treatments for this and other more common forms of endocrine cancers. One promising example is the use of high-throughput screening for compounds that block the Cdk5 protein pathway, the researchers said.

"There are currently two FDA-approved drugs for treating neuroendocrine cancers, but neither of them blocks this specific pathway -- one this study has shown to be a crucial vulnerability in the cancer, if appropriately targeted," Dr. Bibb said. "We were surprised, but encouraged, by the finding because they link the human nervous system to disease processes that include the toughest of all foes, cancer."

More read at :Cancer Cell

Overexpressed protein to be culprit in certain thyroid cancers

'Peanut butter' test can help diagnose Alzheimer's disease, researchers find

A dollop of peanut butter and a ruler can be used to confirm a diagnosis of early stage Alzheimer's disease, University of Florida Health researchers have found...

Of the 24 patients tested who had mild cognitive impairment, which sometimes signals Alzheimer's disease and sometimes turns out to be something else, about 10 patients showed a left nostril impairment and 14 patients did not. The researchers said more studies must be conducted to fully understand the implications.

"At the moment, we can use this test to confirm diagnosis," Stamps said. "But we plan to study patients with mild cognitive impairment to see if this test might be used to predict which patients are going to get Alzheimer's disease."

Stamps and Heilman point out that this test could be used by clinics that don't have access to the personnel or equipment to run other, more elaborate tests required for a specific diagnosis, which can lead to targeted treatment. At UF Health, the peanut butter test will be one more tool to add to a full suite of clinical tests for neurological function in patients with memory disorders.

'Peanut butter' test can help diagnose Alzheimer's disease, researchers find

Ref : http://dx.doi.org/10.1016/j.jns.2013.06.033

Flumazenil reverses stress-triggered anxiety in methamphetamine dependant rats

We know that, Flumazenil (also known as flumazepil, code name Ro 15-1788, trade names Anexate, Lanexat, Mazicon, Romazicon) is abenzodiazepine receptor antagonist primarily available by injection only, and the only benzodiazepine receptor antagonist on the market today.

It was first introduced in 1987 by Hoffmann-La Roche under the trade name Anexate, but only approved by the FDA on December 20, 1991. Some years ago an oral preparation was under development,  though it had low bio-availability and was thus abandoned.

Flumazenil reverses stress-triggered anxiety in methamphetamine dependant rats

Scientists identify new drug for inherited form of cancer with no known cure

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have identified a new drug candidate for an inherited form of cancer with no known cure.  

The new study showed the drug candidate—known as FRAX97 (see structure) slowed the proliferation and progression of tumor cells in animal models of Neurofibromatosis type 2. This inherited type of cancer, caused by mutations in the anti-tumor gene NF2, leads to tumors of the auditory nerve that connects the inner ear to the brain.

The new compound, originally developed to treat neurodegenerative disease, targets a protein family known as p21-activated kinases or PAKs. These kinases (enzymes that add a phosphate group to other proteins and change their function) play a critical role in the development of Neurofibromatosis type 2. PAK1 has also been implicated in the growth of breast and lung cancers.

"Our study shows that if we inhibit these kinases we can counter the formation of tumors in this brain disease," said Joseph Kissil, a TSRI associate professor who led the study.

Scientists identify new drug for inherited form of cancer with no known cure

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

We know that, Lu AE58054 is a potent and selective 5-HT₆ receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia. As of February 2010 it is in phase II clinical trials...

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

In continuation of my update on Tofacitinib

We know that, Tofacitinib (trade name Xeljanz, formerly tasocitinib, CP-690550) is a drug of the janus kinase (JAK) inhibitor class, discoveredand developed by Pfizer. It is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and is being studied for treatment of psoriasis, inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection. Tofacitinib was not approved by the European regulatory agencies because of concerns over efficacy and safety...

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

FDA Approves Adempas to Treat Pulmonary Hypertension

In continuation of my update on Adempas (riociguat)....

Food and Drug Administration today approved Adempas (riociguat) to treat adults with two forms of pulmonary hypertension...

FDA Approves Adempas to Treat Pulmonary Hypertension

Psoriasis Drug May Help Treat Type 1 Diabetes: Report - Drugs.com MedNews

In continuation of my update on alefacept (Amevive)

A drug formerly used to treat the skin condition psoriasis shows promise in treating type 1 diabetes, according to a new study.

Both psoriasis and type 1 diabetes are autoimmune disorders. The drug alefacept (Amevive) is an immune-suppressing drug that was used to treat psoriasis but was withdrawn by its manufacturer in 2011. The drug maker, Astellas Pharma U.S., said at the time that "business needs" led to its decision to pull the drug from the market.

The new study included 49 type 1 diabetes patients at 14 medical centers in the United States. Thirty-three of the patients received weekly injections of alefacept for 12 weeks, followed by a break of 12 weeks and then another 12 weekly doses of the drug. Sixteen patients received a placebo on the same schedule.

The clinical trial's main outcome was a measure of how well the pancreas could secrete insulin in response to food, two hours after eating. Using this measure, the researchers found no significant differences between the two groups of patients. 

Ref : http://www.thelancet.com/journals/landia/article/PIIS2213-8587(13)70111-6/abstract

Psoriasis Drug May Help Treat Type 1 Diabetes: Report  

Adempas drug gets FDA approval for treatment of pulmonary hypertension

The U.S. Food and Drug Administration today approved Adempas (riociguat) to treat adults with two forms of pulmonary hypertension. Pulmonary hypertension is caused by abnormally high blood pressure in the arteries of the lungs.

Adempas drug gets FDA approval for treatment of pulmonary hypertension

2013 Nobel Prize in Chemistry: Multiscale models for complex chemical systems

The work of Karplus, Levitt and Warshel is ground-breaking in that they managed to make Newton's classical physics work side-by-side with the fundamentally different quantum physics. Previously, chemists had to choose to use either or. The strength of classical physics was that calculations were simple and could be used to model really large molecules. Its weakness, it offered no way to simulate chemical reactions. For that purpose, chemists instead had to use quantum physics. But such calculations required enormous computing power and could therefore only be carried out for small molecules.

This year's Nobel Laureates in chemistry took the best from both worlds and devised methods that use both classical and quantum physics. For instance, in simulations of how a drug couples to its target protein in the body, the computer performs quantum theoretical calculations on those atoms in the target protein that interact with the drug. The rest of the large protein is simulated using less demanding classical physics.

Today the computer is just as important a tool for chemists as the test tube. Simulations are so realistic that they predict the outcome of traditional experiments.

Martin Karplus, U.S. and Austrian citizen. Born 1930 in Vienna, Austria. Ph.D. 1953 from California Institute of Technology, CA, USA. Professeur Conventionné, Université de Strasbourg, France and Theodore William Richards Professor of Chemistry, Emeritus, Harvard University, Cambridge, MA, USA.http://chemistry.harvard.edu/people/martin-karplus http://www-isis.u-strasbg.fr/biop/start

Michael Levitt, U.S., Brittish and Israeli citizen. Born 1947 in Pretoria, South Africa. Ph.D. 1971 from University of Cambridge, UK. Robert W. and Vivian K. Cahill Professor in Cancer Research, Stanford University School of Medicine, Stanford, CA, USA. http://med.stanford.edu/profiles/Michael_Levitt

Arieh Warshel, U.S. and Israeli citizen. Born 1940 in Kibbutz Sde-Nahum, Israel. Ph.D. 1969 from Weizmann Institute of Science, Rehovot, Israel. Distinguished Professor, University of Southern California, Los Angeles, CA, USA.http://chem.usc.edu/faculty/Warshel.html

2013 Nobel Prize in Chemistry: Multiscale models for complex chemical systems

Carbon's new champion: Carbyne, a simple chain of carbon atoms, strongest material of all?

Carbyne will be the strongest of a new class of microscopic materials if and when anyone can make it in bulk....

Carbon's new champion: Carbyne, a simple chain of carbon atoms, strongest material of all?

Phase 3 study of idelalisibin reports positive results in CLL patients

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its Phase 3 study (Study 116) evaluating idelalisib in previously-treated chronic lymphocytic leukemia (CLL) patients who are not fit for chemotherapy will be stopped early. This DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progression-free survival in patients receiving idelalisib plus rituximab (see structures I and II respectively) compared to those receiving rituximab alone. 

Phase 3 study of idelalisibin reports positive results in CLL patients

Two drugs in combination improve survival in patients with advanced pancreatic cancer

In continuation of my update on nab-paclitaxel (stands for nab-nanoparticle albumin-bound) and gemcitabine...

Investigators at the Vall d´Hebron University Hospital and the Vall d'Hebron Institute of Oncology (VHIO), have participated in an international phase III study, published in The New England Journal of Medicine. Results show that administering these two drugs in combination significantly improves one- and two-year survival in patients with advanced pancreatic cancer versus gemcitabine alone, the first-line treatment or most standard approach for this type of cancer to date.

The new drug is set to become a reference in advanced pancreatic cancer treatment. A multicentre phase III study, with centers participating from 11 countries in North America, Europe and Australia, shows that the drug combination nab-paclitaxel and gemcitabine is more effective in the treatment of patients with advanced pancreatic cancer than gemcitabine alone, which has been the standard treatment for these patients up until now.

The clinical trial, sponsored by Celgene Corporation, involved 861 patients, half of whom were administered the nab-paclitaxel/gemcitabine combination, while the other half received gemcitabine alone. Median overall survival was 8.5 months for nab-paclitaxel/gemcitabine versus 6.7 months for gemcitabine alone. One-year survival rates were 35% and 22%, respectively, and two-year survival rates were 9% and 4%, respectively. Similar side effects were found in the new drug and gemcitabine alike. The trial report therefore concluded that the nab-paclitaxel/gemcitabine combination significantly improves overall survival and response rate in patients with advanced pancreatic cancer.

Two drugs in combination improve survival in patients with advanced pancreatic cancer

Alkermes' ALKS 5461 drug gets FDA Fast Track status for major depressive disorder

Alkermes' ALKS 5461 drug gets FDA Fast Track status for major depressive disorder

(ALKS 33 -see structure in a combination with buprenorphine -see 2nd structure right- called ALKS 5461)